SCHEMBL6907448

SCHEMBL6907448

CC(=O)Oc1ccc(N(CC(=O)OC(C)C)C(C)=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
TSPO P30536 1/20 0.39
MAPT P10636 3/20 0.38
POLB P06746 3/20 0.38
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HSD17B10 Q99714 2/20 0.38
ELANE P08246 2/20 0.37
MLYCD O95822 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
ALDH1A1 P00352 2/20 0.36
SRD5A1 P18405 1/20 0.36
HSP90AA1 P07900 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5810849 0.84 CA12 (0.45) TSPOMAPTMLYCDTSHRALDH1A1
SCHEMBL6908944 0.84 ALDH1A1 (0.46) LMNAMAPTPOLBPKMSMN1; SMN2
SCHEMBL5812624 0.82 TSHR (0.51) TSPOMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL6905698 0.81 LMNA (0.46) LMNAMAPTPOLBPKMSMN1; SMN2
SCHEMBL6902198 0.80 LMNA (0.47) LMNAMAPTPOLBPKMSMN1; SMN2
SCHEMBL6916598 0.79 LMNA (0.46) LMNAMAPTPOLBPKMSMN1; SMN2
SCHEMBL6908413 0.79 LMNA (0.40) LMNAMAPTPOLBPKMSMN1; SMN2
SCHEMBL11773210 0.74 ELANE (0.41) MAPTPOLBELANEMLYCDMEN1
SCHEMBL6905596 0.71 LMNA (0.45) LMNAMAPTPOLBPKMSMN1; SMN2
SCHEMBL6904246 0.71 ALDH1A1 (0.42) LMNAMAPTPOLBPKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US claimed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP claimed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US claimed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO claimed
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US disclosed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP disclosed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US disclosed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives GRHPR, ARL1, SUCLG1 LMNA 1347/4885TSPO 4700/4885MAPT 4452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.